Calcium intake and vitamin D metabolism and action, in healthy conditions and in prostate cancer

British Journal of Nutrition

Volumn 97, Issue 4, 2007, Pages 611-616

  Bonjour, Jean Philippe ^a   Chevalley, Thierry ^a   Fardellone, Patrice ^b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b AMIENS UNIVERSITY HOSPITAL   (France)

Author keywords

Calcium intake; Prostate cancer; Vitamin D metabolism

Indexed keywords

25 HYDROXYVITAMIN D; CALCIDIOL 1 MONOOXYGENASE; CALCITRIOL; CALCITRIOL DERIVATIVE; CALCIUM; CALCIUM CARBONATE; PARATHYROID HORMONE; PLACEBO; SOMATOMEDIN C; VITAMIN D; VITAMIN D RECEPTOR;

ANTINEOPLASTIC ACTIVITY; CALCIUM INTAKE; CALCIUM METABOLISM; CANCER CELL; CANCER PREVENTION; CANCER RISK; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL; DIET SUPPLEMENTATION; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; HYPOTHESIS; LATITUDE; NONHUMAN; OSTEOPOROSIS; PATHOPHYSIOLOGY; PREVALENCE; PROSTATE CANCER; PROSTATE CARCINOMA; PROTEIN EXPRESSION; REVIEW; SARCOIDOSIS; SEASONAL VARIATION; SIDE EFFECT; TUMOR PROMOTION; VITAMIN BLOOD LEVEL; VITAMIN D METABOLISM;

CALCITRIOL; CALCIUM, DIETARY; DIET; HUMANS; MALE; PROSTATIC NEOPLASMS; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 33947498484     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S0007114507657961     Document Type: Review

References (58)

1. 3 loading and dietary calcium deprivation on plasma 1,25-dihydroxyvitamin D concentrations in healthy adults. J Clin Endocrinol Metab 48, 1008-1016.
2. Ahonen MH, Tenkanen L, Teppo L, Hakama M & Tuohimaa P (2000) Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control 11, 847-852.
3. Balaji KC, Huryk RF, Verhulst S & Fair WR (2001) Growth of heterotopic LNCaP prostate cancer tumor in nude mice is not affected by dietary calcium. Prostate 48, 265-273.
4. Baron JA, Beach M, Mandel JS, et al. (1999) Calcium supplements for the prevention of colorectal adenomas. Calcium Polyp Prevention Study Group. N Engl J Med 340, 101-107.
5. Baron JA, Beach M, Wallace K, Grau MV, Sandler RS, Mandel JS, Heber D & Greenberg ER (2005) Risk of prostate cancer in a randomized clinical trial of calcium supplementation. Cancer Epidemiol Biomarkers Prev 14, 586-589.
6. Barreto AM, Schwartz GG, Woodruff R & Cramer SD (2000) 25-Hydroxyvitamin D3, the prohormone of 1,25-dihydroxyvitamin D3, inhibits the proliferation of primary prostatic epithelial cells. Cancer Epidemiol Biomarkers Prev 9, 265-270.
7. Bell NH (1998) Renal and nonrenal 25-hydroxyvitamin D-1α-hydroxylases and their clinical significance. J Bone Miner Res 13, 350-353.
8. Bell NH, Stem PH, Pantzer E, Sinha TK & DeLuca HF (1979) Evidence that increased circulating 1 α, 25-dihydroxyvitamin D is the probable cause for abnormal calcium metabolism in sarcoidosis. J Clin Invest 64, 218-225.
9. Berndt SI, Carter HB, Landis PK, Tucker KL, Hsieh LJ, Metter EJ & Platz EA (2002) Calcium intake and prostate cancer risk in a longterm aging study: The Baltimore Longitudinal Study of Aging. Urology 60, 1118-1123.
10. Braun MM, Helzlsouer KJ, Hollis BW & Comstock GW (1995) Prostate cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, United States). Cancer Causes Control 6, 235-239.
11. Caverzasio J, Montessuit C & Bonjour JP (1990) Stimulatory effect of insulin-like growth factor-1 on renal Pi transport and plasma 1,25-dihydroxyvitamin D3. Endocrinology 127, 453-459.
12. Chan JM & Giovannucci EL (2001) Dairy products, calcium, and vitamin D and risk of prostate cancer. Epidemiol Rev 23, 87-92.
13. Chan JM, Pietinen P, Virtanen M, Malila N, Tangrea J, Albanes D & Virtamo J (2000) Diet and prostate cancer risk in a cohort of smokers, with a specific focus on calcium and phosphorus (Finland). Cancer Causes Control 11, 859-867.
14. Corder EH, Guess HA, Hulka BS, Friedman GD, Sadler M, Vollmer RT, Lobaugh B, Drezner MK, Vogelman JH & Orentreich N (1993) Vitamin D and prostate cancer: A prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev 2, 467-472.
15. Favus MJ (2003) Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 5th ed., Washington, DC: American Society for Bone and Mineral Research.
16. Feldman D, Malloy P & Gross C (2001) Vitamin D: Biology, action, and clinical implication. In Osteoporosis, pp. 257-303 [R Marcus, D Feldman and J Kelsey, editors]. San Diego, CA: Academic Press.
17. Ferrari SL, Bonjour JP & Rizzoli R (2005) Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 90, 1519-1524.
18. Gallagher JC, Riggs BL, Eisman J, Hamstra A, Arnaud SB & DeLuca HF (1979) Intestinal calcium absorption and serum vitamin D metabolites in normal subjects and osteoporotic patients: Effect of age and dietary calcium. J Clin Invest 64, 729-736.
19. Gann PH, Ma J, Hennekens CH, Hollis BW, Haddad JG & Stampfer MJ (1996) Circulating vitamin D metabolites in relation to subsequent development of prostate cancer. Cancer Epidemiol Biomarkers Prev 5, 121-126.
20. Gao X, LaValley MP & Tucker KL (2005) Prospective studies of dairy product and calcium intakes and prostate cancer risk: A meta-analysis. J Natl Cancer Inst 97, 1768-1777.
21. Gao X, Valley ML & Tucker KL (2006) Prospective studies of dairy and calcium intakes and prostate risk: A meta-analyisis. J Natl Cancer Inst 98, 795.
22. Giovannucci E (2005) The epidemiology of vitamin D and cancer incidence and mortality: A review (United States). Cancer Causes Control 16, 83-95.
23. Giovannucci E, Liu Y, Stampfer MJ & Willett WC (2006) A prospective study of calcium intake and incident and fatal prostate cancer. Cancer Epidemiol Biomarkers Prev 15, 203-210.
24. Giovannucci E, Rimm EB, Wolk A, Ascherio A, Stampfer MJ, Colditz GA & Willett WC (1998) Calcium and fructose intake in relation to risk of prostate cancer. Cancer Res 58, 442-447.
25. Grant WB (2002) An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet-B radiation. Cancer 94, 1867-1875.
26. Gross MD (2005) Vitamin D and calcium in the prevention of prostate and colon cancer: New approaches for the identification of needs. J Nutr 135, 326-331.
27. Guyatt GH, Sackett DL, Sinclair JC, Hayward R, Cook DJ & Cook RJ (1995) Users' guides to the medical literature. IX A method for grading health care recommendations. Evidence-Based Medicine Working Group. JAMA 274, 1800-1804.
28. Heaney RP, Davies KM, Chen TC, Holick MF & Barger-Lux MJ (2003) Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr 77, 204-210.
29. Holick MF (1994) McCollum Award Lecture, 1994: Vitamin D - new horizons for the 21st century. Am J Clin Nutr 60, 619-630.
30. Holick MF (2003) Vitamin D: A millenium perspective. J Cell Biochem 88, 296-307.
31. Hsu JY, Feldman D, McNeal JE & Peehl DM (2001) Reduced 1α-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition. Cancer Res 61, 2852-2856.
32. Jacobs ET, Giuliano AR, Martinez ME, Hollis BW, Reid ME & Marshall JR (2004) Plasma levels of 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D and the risk of prostate cancer. J Steroid Biochem Mol Biol 89-90, 533-537.
33. Kalkwarf HJ & Specker BL (2002) Bone mineral changes during pregnancy and lactation. Endocrine 17, 49-53.
34. Kesse E, Bertrais S, Astorg P, Jaouen A, Arnault N, Galan P & Hercberg S (2006) Dairy products, calcium and phosphorus intake, and the risk of prostate cancer: Results of the French prospective SU.VI.MAX (Supplementation en Vitamines et Mineraux Antioxydants) study. Br J Nutr 95, 539-545.
35. Kristal AR, Cohen JH, Qu P & Stanford JL (2002) Associations of energy, fat, calcium, and vitamin D with prostate cancer risk. Cancer Epidemiol Biomarkers Prev 11, 719-725.
36. Ma JF, Nonn L, Campbell MJ, Hewison M, Feldman D & Peehl DM (2004) Mechanisms of decreased Vitamin D 1α-hydroxylase activity in prostate cancer cells. Mol Cell Endocrinol 221, 67-74.
37. Maierhofer WJ, Gray RW & Lemann J Jr (1984) Phosphate deprivation increases serum 1,25-(OH)2-vitamin D concentrations in healthy men. Kidney Int 25, 571-575.
38. Miller GJ (1998) Vitamin D and prostate cancer: Biologic interactions and clinical potentials. Cancer Metastasis Rev 17, 353-360.
39. Nomura AM, Stemmermann GN, Lee J, Kolonel LN, Chen TC, Turner A & Holick MF (1998) Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States). Cancer Causes Control 9, 425-432.
40. Papapoulos SE, Clemens TL, Fraher LJ, Lewin IG, Sandler LM & O'Riordan JL (1979) 1, 25-Dihydroxycholecalciferol in the pathogenesis of the hypercalcaemia of sarcoidosis. Lancet i, 627-630.
41. Peehl DM & Feldman D (2003) The role of vitamin D and retinoids in controlling prostate cancer progression. Endocr Relat Cancer 10, 131-140.
42. Platz EA, Leitzmann MF, Hollis BW, Willett WC & Giovannucci E (2004) Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer. Cancer Causes Control 15, 255-265.
43. Qin LQ, Wang PY, Kaneko T, Hoshi K & Sato A (2004a) Estrogen: One of the risk factors in milk for prostate cancer. Med Hypotheses 62, 133-142.
44. Qin LQ, Xu JY, Wang PY, Kaneko T, Hoshi K & Sato A (2004b) Milk consumption is a risk factor for prostate cancer: Meta-analysis of case-control studies. Nutr Cancer 48, 22-27.
45. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM & Egger M (2004) Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: Systematic review and meta-regression analysis. Lancet 363, 1346-1353.
46. Rodriguez C, McCullough ML, Mondul AM, Jacobs EJ, Fakhrabadi-Shokoohi D, Giovannucci EL, Thun MJ & Calle EE (2003) Calcium, dairy products, and risk of prostate cancer in a prospective cohort of United States men. Cancer Epidemiol Biomarkers Prev 12, 597-603.
47. Schuurman AG, van den Brandt PA, Dorant E & Goldbohm RA (1999) Animal products, calcium and protein and prostate cancer risk in The Netherlands Cohort Study. Br J Cancer 80, 1107-1113.
48. Schwartz GG & Hulka BS (1990) Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res 10, 1307-1311.
49. Schwartz GG, Whitlatch LW, Chen TC, Lokeshwar BL & Holick MF (1998) Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3. Cancer Epidemiol Biomarkers Prev 7, 391-395.
50. Severi G, English DR, Hopper JL & Giles GG (2006a) Re: Prospective studies of dairy product and calcium intakes and prostate cancer risk: A meta-analysis. J Natl Cancer Inst 98, 794-795, author reply 795.
51. Severi G, Morris HA, MacInnis RJ, English DR, Tilley WD, Hopper JL, Boyle P & Giles GG (2006b) Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 15, 1137-1141.
52. Sonn GA, Aronson W & Litwin MS (2005) Impact of diet on prostate cancer: a review. Prostate Cancer Prostatic Dis 8, 304-310.
53. Tavani A, Bertuccio P, Bosetti C, Talamini R, Negri E, Franceschi S, Montella M & La Vecchia C (2005) Dietary intake of calcium, vitamin D, phosphorus and the risk of prostate cancer. Eur Urol 48, 27-33.
54. Tavani A, Gallus S, Franceschi S & La Vecchia C (2001) Calcium, dairy products, and the risk of prostate cancer. Prostate 48, 118-121.
55. Tseng M, Breslow RA, Graubard BI & Ziegler RG (2005) Dairy, calcium, and vitamin D intakes and prostate cancer risk in the National Health and Nutrition Examination Epidemiologic Follow-up Study cohort. Am J Clin Nutr 81, 1147-1154.
56. Tuohimaa P, Tenkanen L, Ahonen M, et al. (2004) Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: A longitudinal, nested case-control study in the Nordic countries. Int J Cancer 108, 104-108.
57. Woo TC, Choo R, Jamieson M, Chander S & Vieth R (2005) Pilot study: potential role of vitamin D (cholecalciferol) in patients with PSA relapse after definitive therapy. Nutr Cancer 51, 32-36.
58. Young MV, Schwartz GG, Wang L, Jamieson DP, Whitlatch LW, Flanagan JN, Lokeshwar BL, Holick MF & Chen TC (2004) The prostate 25-hydroxyvitamin D-1 α-hydroxylase is not influenced by parathyroid hormone and calcium: implications for prostate cancer chemoprevention by vitamin D. Carcinogenesis 25, 967-971.